Search - tctmd.com

Displaying 1 - 20 of 60

Sort: Relevancy | Date

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

September 05, 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

News Conference News ESC 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

Michael O'Riordan

August 31, 2025

Starting SGLT2 inhibitors in the Hospital for Acute HF Gains Support

News Conference News ESC 2025

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

August 30, 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

News Conference News ESC 2024

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

August 31, 2024

Polypills Show Promise in Diverse Hypertensive Patient Groups

News Conference News ESC 2024

Polypills Show Promise in Diverse Hypertensive Patient Groups

August 31, 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

News Conference News ESC 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

Michael O'Riordan

August 30, 2024

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

News Conference News ESC 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Michael O'Riordan

August 31, 2023

Four Intravascular Imaging Studies Shared the ESC Spotlight, Yet Shadows Persist

News Conference News ESC 2023

Four Intravascular Imaging Studies Shared the ESC Spotlight, Yet Shadows Persist

August 27, 2023

IV Iron in HF Misses (Again) in HEART-FID, but Meta-analysis Sees a Role

News Conference News ESC 2023

IV Iron in HF Misses (Again) in HEART-FID, but Meta-analysis Sees a Role

August 26, 2023

COP-AF: Colchicine Doesn’t Cut Post-Op AF or Myocardial Injury

News Conference News ESC 2023

COP-AF: Colchicine Doesn’t Cut Post-Op AF or Myocardial Injury

Michael O'Riordan

August 25, 2023

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

News Conference News ESC 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

August 30, 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

‘Hot’ Plaque on Noninvasive PET May Presage MI, CV Death: PRE18FFIR

News Conference News ESC 2022

‘Hot’ Plaque on Noninvasive PET May Presage MI, CV Death: PRE18FFIR

August 28, 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

August 27, 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

News Conference News ESC 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

August 27, 2022

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

September 02, 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

News Conference News ESC 2021

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

August 31, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.